About Us

the Background

Biograil was established in 2019 and is a spin-off from Egalet/Zyla Life Sciences. Biograil is a pre-clinical stage pharmaceutical company leveraging its proprietary BIONDD technology to unlock the potential of transforming markets of injectable pharmaceutical products into convenient oral capsules.


the Team

Karsten Lindhardt
Chief Executive Officer & Founder

Nikolaj Skak
Chief Technology Officer & Founder

Lars Hellerung Christiansen
Advisor Business Development & Founder

John M. Barberich
Consulting Chief Financial Officer & Founder

Karsten Lindhardt, CEO

20+ years in pharmaceutical industry, Head of R&D and CSO Egalet, senior positions in Novo Nordisk, Ferring, Prosidion & Curalogic


Nikolaj Skak, CTO

15+ years in pharmaceutical industry, Head of Pharmaceutical Development Egalet, senior positions in Veloxis


Lars Hellerung Christiansen, Advisor BD

30+ years of experience as serial entrepreneur, Co-founder Symphogen , ACADIA, Zealand Pharm, and others


John M. Barberich: Consulting CFO

30+ years of experience in biotech and investing, Co-founder and former CFO, ACADIA Pharmaceuticals, Venture Partner, Nordic Biotech, large pharma transactions, Transaction Executive with The Henley Group

the Investors

Biograil ApS
Baldersbuen 2
2640 Hedehusene
Denmark

E: info@biograil.com
T: +45 21 66 39 41